# Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

> **NCT01898156** · PHASE1,PHASE2 · TERMINATED · sponsor: **Kyowa Kirin Korea Co., Ltd.** · enrollment: 37 (actual)

## Conditions studied

- Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma
- Phase 2 Portion : Small Cell Lung Cancer(SCLC)

## Interventions

- **DRUG:** BIW-8962

## Key facts

- **NCT ID:** NCT01898156
- **Lead sponsor:** Kyowa Kirin Korea Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** lack of efficacy
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01898156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01898156, "Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01898156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*